<DOC>
	<DOCNO>NCT02255435</DOCNO>
	<brief_summary>Friedreich 's ataxia autosomal recessive cerebellar ataxia cause triplet-repeat expansion . The causative mutation trinucleotide ( GAA ) repeat expansion first intron frataxin gene , lead impaired transcription frataxin . The pathological consequence frataxin deficiency include severe disruption iron-sulfur cluster biosynthesis , mitochondrial iron overload couple cellular iron dysregulation , increased sensitivity oxidative stress . A hallmark Friedreich 's ataxia impairment antioxidative defense mechanism , play major role disease progression . Studies demonstrate nuclear factor erythroid-derived 2-related factor 2 ( Nrf2 ) signal grossly impaired patient Friedreich 's ataxia . Therefore , ability omaveloxolone ( RTA 408 ) activate Nrf2 induce antioxidant target gene hypothesize therapeutic patient Friedreich 's ataxia . This 2-part study evaluate efficacy , safety , pharmacodynamics omaveloxolone ( RTA 408 ) treatment patient Friedreich 's ataxia . Part 1 : The first part study randomize , placebo-controlled , double-blind , dose-escalation study evaluate safety omaveloxolone ( RTA 408 ) various dos patient Friedreich 's ataxia . Part 2 : The second part study randomize , placebo-controlled , double-blind , parallel study evaluate safety , efficacy , pharmacodynamics 2 dose level omaveloxolone ( RTA 408 ) patient Friedreich 's ataxia . Eligible patient Part 2 randomized 1:1:1 receive omaveloxolone ( RTA 408 ) ( one 2 dos choose Part 1 ) , placebo .</brief_summary>
	<brief_title>RTA 408 Capsules Patients With Friedreich 's Ataxia - MOXIe</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<criteria>1 . Have genetically confirm Friedreich 's ataxia 2 . Have modify FARS score ≥10 ≤80 3 . Be male female ≥16 year age ≤40 year age 4 . Have change exercise regimen within 30 day prior Study Day 1 willing remain exercise regimen 16week study period 5 . Have ability complete maximal exercise test 6 . Be able swallow capsule 1 . Have uncontrolled diabetes ( HbA1c &gt; 11.0 % ) 2 . Have Btype natriuretic peptide value &gt; 200 pg/mL 3 . Have history clinically significant leftsided heart disease and/or clinically significant cardiac disease 4 . Have know active fungal , bacterial , and/or viral infection , include human immunodeficiency virus hepatitis virus ( B C ) 5 . Have know suspected active drug alcohol abuse 6 . Have clinically significant abnormality clinical hematology biochemistry , include limited elevation great 1.5 time upper limit normal aspartate aminotransferase , alanine aminotransferase creatinine 7 . Have abnormal laboratory test value serious preexist medical condition , opinion investigator , would put patient risk study enrollment 8 . Have take follow drug within 7 day prior Study Day 1 plan take drug time study participation : 1 . Sensitive substrate cytochrome P450 2C8 3A4 ( e.g. , repaglinide , midazolam , sildenafil ) 2 . Substrates pglycoprotein transporter ( e.g. , ambrisentan , digoxin ) 9 . Have participate interventional clinical study within 30 day prior Study Day 1 10 . Have cognitive impairment may preclude ability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>RTA 408</keyword>
	<keyword>RTA 408 Capsules</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>Mitochondrial dysfunction</keyword>
	<keyword>omaveloxolone</keyword>
</DOC>